Abstract Details

Title School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 173

Objective

Our aims were to investigate school performance, psychiatric comorbidity and healthcare utilization following pediatric multiple sclerosis (MS) and to differentiate between disability in MS and that arising from a non-brain-related chronic disease.

Background Pediatric MS may hamper educational achievements due to psychiatric comorbidity and cognitive impairment.

Design/Methods We included all children (<18 years) with MS onset during 2008–15 in Denmark with a medical record-validated MS diagnosis. The control groups were children from the general population or children with non-brain-related chronic diseases. Outcomes were register-based on 9–12 grade point average, psychiatric comorbidity, and healthcare visits.

Results Cohorts were children with MS (n=92), control children matched to children with MS (n=920), children with non-brain-related chronic diseases (n=9,108), and “healthy” children with neither MS nor brain-related chronic disease (n=811,464). School performance in grades 9–12 was similar, but children with MS compared with those with non-brain-related chronic disease had an almost doubled hazard for psychiatric comorbidity (hazard ratio=1.87; 95% confidence interval=1.38?2.53; p<0.0001) and a higher rate of all hospital visits (p<0.0001) but a lower rate of hospital admissions (p=0.001).

Conclusions

Children with MS have a seemingly standard school performance but increased psychiatric comorbidity and a high rate of healthcare utilization.

Authors/Disclosures
Magnus Spangsberg Boesen, MD (Herlev Hospital) PRESENTER	Dr. Spangsberg Boesen has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Melinda Magyari, MD	Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.

��ɫ��

��ɫ��